Drug intelligence / Profile preview

ciprofloxacin + rifampin

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

Ciprofloxacin + rifampin is a combination antibiotic therapy used primarily for treating serious bacterial infections. Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while rifampin inhibits bacterial RNA polymerase. This combination has been studied for treating methicillin-resistant Staphylococcus aureus (MRSA) infections, endocarditis, and other serious bacterial infections. The combination may help reduce the emergence of resistance to ciprofloxacin, though its efficacy can be unpredictable and sometimes detrimental compared to monotherapy.

Targets

rpoB (DNA-directed RNA polymerase subunit beta)DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on ciprofloxacin + rifampin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + rifampin.

Explore the full profile